Drug Trial Radar · NCT02500407
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Last checked: Nov 20, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
713
Actual
Start
Sep 15, 2015
Primary completion
May 21, 2024
Study completion Sep 1, 2025
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jul 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Conditions
- Lymphocytic Leukemia, Chronic
- Lymphoma, Non Hodgkin
Interventions
BTCT4465A (Mosunetuzumab) IVDrug
Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via IV infusion.
AtezolizumabDrug
Participants assigned to an atezolizumab combination group will receive atezolizumab 1200 mg administered as an IV infusion in combination with BTCT4465A (Mosunetuzumab).
BTCT4465A (Mosunetuzumab) SCDrug
Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) of BTCT4465A (Mosunetuzumab)Time frame: BTCT4465A (Mosunetuzumab) single agent: Cycle 1; BTCT4465A (Mosunetuzumab) in combination with atezolizumab: during the first cycle that BTCT4465A (Mosunetuzumab) and atezolizumab are administered concurrently (cycle length = 21 days)
- Percentage of Participants With Adverse EventsTime frame: Cycle 1 Day 1 until 90 days after the last infusion (cycle length = 21 days; up to approximately 14 months)
- BTCT4465A (Mosunetuzumab) Serum ConcentrationTime frame: Baseline up to 30 days after the last infusion of BTCT4465A (Mosunetuzumab) (up to approximately 12 months)
- Atezolizumab Serum ConcentrationTime frame: Baseline up to 30 days after the last infusion of BTCT4465A (Mosunetuzumab) (up to approximately 12 months)
- Percentage of Participants with Complete Response as Assessed Using Standard Criteria for NHLTime frame: Baseline up to approximately 4 years (assessed at screening and then every 3 months until disease progression, start of new anti-cancer therapy, or withdrawal)
Locations
35 sites in 7 countries. Site status is shown where the registry gives one.
University of California San Diego Moores Cancer Center
La Jolla, California
Sansum Medical Clinic, Inc.
Santa Barbara, California
Rocky Mountain Cancer Center
Denver, Colorado
Yale University School Of Medicine
New Haven, Connecticut
Hackensack University Medical Center
Hackensack, New Jersey
Memorial Sloan Kettering Bergen
Montvale, New Jersey
Memorial Sloan Kettering Cancer Center - Commack
Commack, New York
Memorial Sloan Kettering Cancer Center at Westchester
Harrison, New York
New York Uni Medical Center
New York, New York
Willamette Valley Cancer Insitute and Research Center
Springfield, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
Icon Cancer Care South Brisbane
South Brisbane, Queensland, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
St. Vincent's Hospital Melbourne
Fitzroy, South Australia, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Monash Health Clinical Trial Pharmacy department
Clayton, Victoria, Australia
The Perth Blood Institute
Nedlands, Western Australia, Australia
Princess Margaret Hospital
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Universitatsklinikum Koln
Cologne, Germany
Universitätsklinikum Heidelberg
Heidelberg, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
Mainz, Germany
Klinikum der Universität München, Campus Großhadern
München, Germany
Seoul National University Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital Universitario Vall d Hebron
Barcelona, Spain
Hospital Universitario La Paz
Madrid, Spain
Complejo Asistencial Universitario de Salamanca
Salamanca, Spain
Clínica Universidad de Navarra
Pamplona, Navarre, Spain
Barts Cancer Institute
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Royal Marsden Hospital;Institute of Cancer Research
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.